Table 2.
Clinical Characteristics and Mortality in Liver Transplant Recipients With COVID-19
| Overall† | Deceased∗ (n = 27) | Survived (n = 93) | P value | |
|---|---|---|---|---|
| Comorbidities | ||||
| Hypertension (%) | 51.4 | 69.2 | 47.6 | .05 |
| Diabetes mellitus (%) | 42.1 | 36.2 | 15.0 | .01 |
| Chronic kidney disease (%) | 29.1 | 40 | 30.4 | .44 |
| Overweight (BMI ≥ 25 kg/m2, %) | 52.5 | 61.9 | 46.5 | .21 |
| Cardiovascular disease (%) | 14.3 | 31.8 | 18.7 | .18 |
| Symptoms on Presentation | ||||
| Fever (%) | 66.7 | 57.1 | 68.3 | .43 |
| Dyspnea (%) | 34.0 | 88.9 | 36.7 | <.001 |
| Diarrhea (%) | 28.4 | 42.9 | 36.7 | .94 |
| Immunosuppression Used | ||||
| Corticosteroid use (%) | 42.2 | 56.5 | 38.4 | .09 |
| Tacrolimus/cyclosporin (%) | 87.5 | 88.5 | 89.9 | .83 |
| Mycophenolate (%) | 53.2 | 60.9 | 51.2 | .41 |
| mToR inhibitor (%) | 9.9 | 6.2 | 10.9 | .58 |
Abbreviations: BMI, Body mass index; COVID-19, coronavirus disease 2019; mToR, mammalian target of rapamycin.
∗
Data from Pereira et al [9] with “severe disease - defined as ICU admission, intubation or death,” were presumed deceased in this analysis (n = 4).
†
Data from Belli et al [15] reported overall outcomes and did not stratify comorbidities, symptoms on presentation, and immunosuppression used based on mortality. Denominators used are included in supplementary table 6.